Overview
Cambridge Healthcare Research helps pharmaceutical, biotechnology, medical device, and life-science companies make strategic decisions. Its offerings come from two main arms: Solici for strategic competitive intelligence and Vox.Bio for market research, plus a Pricing & Market Access team. The firm tests hypotheses through iterative research and delivers evidence-based recommendations to inform product strategy, commercialization, portfolio planning, and landscape assessments. It differentiates itself with a house-of-brands structure, a global consulting footprint, and a proven track record, including the Queen’s Award for Enterprise, all aimed at helping clients understand market dynamics, regulatory and payer perspectives, to improve outcomes from development through product lifecycle.
Work here?Claim your company
Simplify's take
What believers are saying
- GlobalData said CHR added £4.2 million revenue and £0.1 million profit post-acquisition.
- Management targets deeper pharmaceutical relationships using CHR with proprietary data, technology, and AI.
- CHR still serves major pharma across 30 countries, supporting recurring specialist demand.
What critics are saying
- Integration with Deallus risks culture clashes and client churn during 2026-2027.
- GlobalData paid £21.3 million for CHR, compressing returns if cross-sell stalls.
- CHR's former founders resigned control on 1 April 2026, ending independent strategic direction.
What makes Cambridge Healthcare Research unique
- GlobalData acquired CHR on 1 April 2026, folding it into a larger CI platform.
- CHR pairs Solici competitive intelligence with Vox.Bio market research for life-science clients.
- Matteo Perucchini now leads GlobalData Healthcare Competitive Intelligence after building CHR to 160 staff.
Help us improve and share your feedback! Did you find this helpful?